ArticleNpj imaging2025
Phosphatidylserine exposure and plasma membrane perforation as ferroptotic signatures for in vivo imaging.
Article in Npj imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Sustained Ion Imbalances Enhance Ferroptosis.bioRxiv : the preprint server for biology · 2026Article
- Article
- Targeting SQLE-Mediated Cholesterol Metabolism to Promote Oxidative Stress and Attenuate Drug Resistance in Osteosarcoma.Antioxidants (Basel, Switzerland) · 2026Article
- Comparative Functional Effects of Abemaciclib and Arcyriaflavin A inInternational journal of molecular sciences · 2026Article
- Extracellular Vesicles in Myocardial Infarction: Dual Role in Ferroptosis Regulation and In Vivo Imaging.Diagnostics (Basel, Switzerland) · 2026Review
- Evidence for a Cytokine-Sensitive Network of Iron-Associated Genes That Protects Pancreatic Islets Against Ferroptosis.Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ferroptosis emerged as a cell death modality against cancer, but there are currently no available biomarkers for imaging ferroptosis-based therapies. To address this, we evaluated phosphatidylserine exposure and perforation of lipid membranes during ferroptosis to explore potential targeting opportunities. We demonstrated that nano-sized gaps at late stage ferroptosis can serve as entry points for dyes that can bind to intracellular structures. These changes were accompanied with cellular signaling components similar to platelet activation, with phosphatidylserine exposure on the cell surface as a potential target for imaging programed cell death, including ferroptosis. We employed a novel tumor-seeking dye CJ215 that can also label apoptotic cells and showed that CJ215 accumulates in ferroptotic cells both in vitro and in vivo by binding to phosphatidylserine, which can be prevented with ferroptosis inhibition. Since phosphatidylserine exposure also occurs during apoptosis, CJ215 can monitor both apoptosis and ferroptosis-based therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.